Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
8.01
-0.15 (-1.84%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Eupraxia Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Eupraxia Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $16.35. The average 1-year stock price forecast is 104.12% higher than the current stock price, while the lowest is $11 (+37.33%) and the highest is $25 (+212.11%).
Price Target: $16.35 (+104.12%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Eupraxia Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 11 | 11 | 11 | 12 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $11 | Buy | Maintains | $11 | +37.33% | Sep 22, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 27, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $16 | Buy | Maintains | $16 | +99.75% | Aug 27, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $19 | Buy | Reiterates | $19 | +137.20% | Aug 12, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $17 | Buy | Maintains | $17 | +112.23% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
548.87K
EPS This Year
-0.96
from -1.00
EPS Next Year
-1.03
from -0.96
EPS and Forward PE are based on non-GAAP adjusted numbers.